| ［1］ |
Miossec P, Kolls JK. Targeting IL⁃17 and TH17 cells in chronic inflammation［J］. Nat Rev Drug Discov, 2012,11（10）:763⁃776. doi: 10.1038/nrd3794.
|
| ［2］ |
Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL⁃17+ T helper cells［J］. Cell, 2006,126（6）:1121⁃1133. doi: 10.1016/j.cell.2006.07.035.
|
| ［3］ |
Álvarez⁃Salamero C, Castillo⁃González R, Pastor⁃Fernández G, et al. IL⁃23 signaling regulation of pro⁃inflammatory T⁃cell migration uncovered by phosphoproteomics［J/OL］. PLoS Biol, 2020,18（3）:e3000646. doi: 10.1371/journal.pbio.3000646.
|
| ［4］ |
Mattii M, Lovászi M, Garzorz N, et al. Sebocytes contribute to skin inflammation by promoting the differentiation of T helper 17 cells［J］. Br J Dermatol, 2018,178（3）:722⁃730. doi: 10.1111/bjd.15879.
|
| ［5］ |
Lee JY, Hall JA, Kroehling L, et al. Serum amyloid a proteins induce pathogenic Th17 cells and promote inflammatory disease［J］. Cell, 2020,180（1）:79⁃91.e16. doi: 10.1016/j.cell.2019.11. 026.
|
| ［6］ |
Bernink JH, Ohne Y, Teunissen M, et al. c⁃Kit⁃positive ILC2s exhibit an ILC3⁃like signature that may contribute to IL⁃17⁃mediated pathologies［J］. Nat Immunol, 2019,20（8）:992⁃1003. doi: 10.1038/s41590⁃019⁃0423⁃0.
|
| ［7］ |
Kannan AK, Su Z, Gauvin DM, et al. IL⁃23 induces regulatory T cell plasticity with implications for inflammatory skin diseases［J］. Sci Rep, 2019,9（1）:17675. doi: 10.1038/s41598⁃019⁃53240⁃z.
|
| ［8］ |
McGowan J, Peter C, Kim J, et al. 14⁃3⁃3ζ⁃TRAF5 axis governs interleukin⁃17A signaling［J］. Proc Natl Acad Sci U S A, 2020,117（40）:25008⁃25017. doi: 10.1073/pnas.2008214117.
|
| ［9］ |
Herjan T, Hong L, Bubenik J, et al. IL⁃17⁃receptor⁃associated adaptor Act1 directly stabilizes mRNAs to mediate IL⁃17 inflammatory signaling［J］. Nat Immunol, 2018,19（4）:354⁃365. doi: 10.1038/s41590⁃018⁃0071⁃9.
|
| ［10］ |
Borek I, Köffel R, Feichtinger J, et al. BMP7 aberrantly induced in the psoriatic epidermis instructs inflammation⁃associated Langerhans cells［J］. J Allergy Clin Immunol, 2020,145（4）:1194⁃1207. doi: 10.1016/j.jaci.2019.12.011.
|
| ［11］ |
Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in paediatric patients （≥ 6 to < 12 years of age）: efficacy, safety, pharmacokinetic and biomarker results from the open⁃label CADMUS Jr study［J］. Br J Dermatol, 2020,183（4）:664⁃672. doi: 10.1111/bjd.19018.
|
| ［12］ |
Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate⁃to⁃severe plaque psoriasis （UltIMMa⁃1 and UltIMMa⁃2）: results from two double⁃blind, randomised, placebo⁃controlled and ustekinumab⁃controlled phase 3 trials［J］. Lancet, 2018,392（10148）:650⁃661. doi: 10.1016/S0140⁃6736（18）31713⁃6.
|
| ［13］ |
Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
|
| ［14］ |
Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis （BE READY）: a multicentre, double⁃blind, placebo⁃controlled, randomised withdrawal phase 3 trial［J］. Lancet, 2021,397（10273）:475⁃486. doi: 10.1016/S0140⁃6736（21）00126⁃4.
|
| ［15］ |
Tomalin LE, Russell CB, Garcet S, et al. Short⁃term transcriptional response to IL⁃17 receptor⁃A antagonism in the treatment of psoriasis［J］. J Allergy Clin Immunol, 2020,145（3）:922⁃932. doi: 10.1016/j.jaci.2019.10.041.
|
| ［16］ |
Paul C, Griffiths C, van de Kerkhof P, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA⁃S, a phase 3 study［J］. J Am Acad Dermatol, 2019,80（1）:70⁃79.e3. doi: 10.1016/j.jaad.2018. 06.039.
|
| ［17］ |
Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis （BE VIVID）: efficacy and safety from a 52⁃week, multicentre, double⁃blind, active comparator and placebo controlled phase 3 trial［J］. Lancet, 2021,397（10273）:487⁃498. doi: 10.1016/S0140⁃6736（21）00125⁃2.
|
| ［18］ |
Bai F, Li GG, Liu Q, et al. Short⁃term efficacy and safety of IL⁃17, IL⁃12/23, and IL⁃23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta⁃analysis of randomized controlled trials［J］. J Immunol Res, 2019,2019:2546161. doi: 10.1155/2019/2546161.
|
| ［19］ |
Chan TC, Sanyal RD, Pavel AB, et al. Atopic dermatitis in Chinese patients shows T（H）2/T（H）17 skewing with psoriasiform features［J］. J Allergy Clin Immunol, 2018,142（3）:1013⁃1017. doi: 10.1016/j.jaci.2018.06.016.
|
| ［20］ |
Tsoi LC, Rodriguez E, Stölzl D, et al. Progression of acute⁃to⁃chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses［J］. J Allergy Clin Immunol, 2020,145（5）:1406⁃1415. doi: 10.1016/j.jaci.2019.11. 047.
|
| ［21］ |
Noda S, Hashim PW, Khattri S, et al. Successful use of secukinumab in an Asian patient with severe refractory atopic dermatitis［J］. J Invest Dermatol, 2016,136（5）:S40⁃S40. doi:10.1016/j.jid.2016.02.253.
|
| ［22］ |
Ungar B, Pavel AB, Li R, et al. Phase 2 randomized, double⁃blind study of IL⁃17 targeting with secukinumab in atopic dermatitis［J］. J Allergy Clin Immunol, 2021,147（1）:394⁃397. doi: 10.1016/j.jaci.2020.04.055.
|
| ［23］ |
Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases［J］. J Dermatol, 2018,45（6）:732⁃734. doi: 10.1111/1346⁃8138. 14295.
|
| ［24］ |
Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. Exp Dermatol, 2017,26（1）:28⁃35. doi: 10.1111/exd.13112.
|
| ［25］ |
Saeki H, Kabashima K, Tokura Y, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double⁃blind, placebo⁃controlled, phase II study［J］. Br J Dermatol, 2017,177（2）:419⁃427. doi: 10.1111/bjd. 15493.
|
| ［26］ |
Moran B, Sweeney CM, Hughes R, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti⁃TNF therapy［J］. J Invest Dermatol, 2017,137（11）:2389⁃2395. doi: 10.1016/j.jid.2017.05.033.
|
| ［27］ |
Matusiak Ł, Szczęch J, Bieniek A, et al. Increased interleukin （IL）⁃17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti⁃IL⁃17 agents［J］. J Am Acad Dermatol, 2017,76（4）:670⁃675. doi: 10.1016/j.jaad.2016.10.042.
|
| ［28］ |
Jenei A, Dajnoki Z, Medgyesi B, et al. Apocrine gland⁃rich skin has a non⁃inflammatory IL⁃17⁃related immune milieu, that turns to inflammatory IL⁃17⁃mediated disease in hidradenitis suppurativa［J］. J Invest Dermatol, 2019,139（4）:964⁃968. doi: 10.1016/j.jid.2018.10.020.
|
| ［29］ |
Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open⁃label trial［J］. J Am Acad Dermatol, 2020,82（6）:1524⁃1526. doi: 10.1016/j.jaad.2020.02.005.
|
| ［30］ |
Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open⁃label cohort study［J］. J Am Acad Dermatol, 2020,83（5）:1341⁃1348. doi: 10.1016/j.jaad. 2020.05.007.
|
| ［31］ |
Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum［J］. Br J Dermatol, 2016,174（4）:839⁃846. doi: 10.1111/bjd.14338.
|
| ［32］ |
Shi J, Ma X, Su Y, et al. MiR⁃31 mediates inflammatory signaling to promote re⁃epithelialization during skin wound healing［J］. J Invest Dermatol, 2018,138（10）:2253⁃2263. doi: 10.1016/j.jid.2018.03.1521.
|
| ［33］ |
Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23⁃helper T Cell 17 axis as a treatment target for pityriasis rubra pilaris［J］. JAMA Dermatol, 2017,153（4）:304⁃308. doi: 10. 1001/jamadermatol.2016.5384.
|
| ［34］ |
Haynes D, Strunck JL, Topham CA, et al. Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single⁃arm trial［J］. JAMA Dermatol, 2020,156（6）:668⁃675. doi: 10.1001/jamadermatol.2020.0932.
|
| ［35］ |
De Felice C, Graceffa D, Morrone A, et al. Familial pityriasis rubra pilaris successfully treated with brodalumab［J］. Int J Dermatol, 2020,59（7）:885⁃887. doi: 10.1111/ijd.14857.
|
| ［36］ |
Ricar J, Cetkovska P. Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab［J］. Br J Dermatol, 2021,184（5）:e148. doi: 10.1111/bjd.19681.
|
| ［37］ |
Pilz AC, Seiringer P, Biedermann T, et al. Treatment of pityriasis rubra pilaris with guselkumab［J］. JAMA Dermatol, 2019,155（12）:1424⁃1426. doi: 10.1001/jamadermatol.2019.2774.
|
| ［38］ |
Lwin SM, Hsu CK, Liu L, et al. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14［J］. Br J Dermatol, 2018,178（4）:969⁃972. doi: 10. 1111/bjd.15462.
|
| ［39］ |
Firinu D, Barca MP, Lorrai MM, et al. TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome［J］. Autoimmunity, 2014,47（6）:389⁃394. doi: 10.3109/08916934. 2014.906582.
|
| ［40］ |
Agak GW, Kao S, Ouyang K, et al. Phenotype and antimicrobial activity of Th17 cells induced by propionibacterium acnes strains associated with healthy and acne skin［J］. J Invest Dermatol, 2018,138（2）:316⁃324. doi: 10.1016/j.jid.2017.07.842.
|
| ［41］ |
Wendling D, Aubin F, Verhoeven F, et al. IL⁃23/Th17 targeted therapies in SAPHO syndrome. A case series［J］. Joint Bone Spine, 2017,84（6）:733⁃735. doi: 10.1016/j.jbspin.2017.05.016.
|
| ［42］ |
Wang L, Sun B, Li C. Clinical and radiological remission of osteoarticular and cutaneous lesions in SAPHO patients treated with secukinumab: a case series［J］. J Rheumatol, 2021,48（6）:953⁃955. doi: 10.3899/jrheum.201260.
|
